Results 21 to 30 of about 1,518,675 (340)

Covid 19 Vaccine - boon or a bane? [PDF]

Perspectives In Medical Research, 2020
The global struggle against corona virus disease 2019(COVID19) is now in its 8th month since the pandemic virus SARS –COV2 has first emerged.The severe economic,personal and psychological adverse effects of shutdowns and social distancing make these ...
Kasturi Ravinder Reddy1 , Samkisha Earna2
doaj   +1 more source

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting

New England Journal of Medicine, 2021
Background Preapproval trials showed that messenger RNA (mRNA)–based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety profile, yet these trials were subject to size and patient-mix limitations. An evaluation
Noam Barda, Noa Dagan, Y. Ben-Shlomo, Eldad Kepten, Jacob G Waxman, Reut Ohana, M. Hernán, M. Lipsitch, I. Kohane, D. Netzer, Ben Y. Reis, R. Balicer   +11 more
semanticscholar   +1 more source

Efficacy of COVID-19 vaccines

Microbial Pathogenesis, 2022
As of 2022, the global population has access to several mRNA and traditional inactivated vaccines. However, their effectiveness in preventing infection, hospitalization, and COVID-associated mortality in Jordan has yet to be evaluated. The purpose of this observational study was to evaluate the relative effectiveness of three approved vaccines against ...
Mohamed J. Saadh, Saif Aldeen Jaber
openaire   +2 more sources

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

New England Journal of Medicine, 2020
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic.
F. Polack, Stephen J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, John L. Perez, Gonzalo Pérez Marc, E. Moreira, C. Zerbini, R. Bailey, K. Swanson, Satrajit Roychoudhury, K. Koury, Ping Li, W. Kalina, David Cooper, R. Frenck, L. Hammitt, Ö. Türeci, H. Nell, A. Schaefer, S. Ünal, D. Tresnan, Susan H. Mather, P. Dormitzer, U. Şahin, K. Jansen, W. Gruber   +28 more
semanticscholar   +1 more source

COVID‐19: vaccine’s progress [PDF]

Microbial Biotechnology, 2021
Summary Under the pressure of the COVID‐19 pandemic, vaccines were developed and rolled out into mass vaccination campaigns at incredible speed. What normally takes a decade was worked out within a year. Vaccines were produced along many different platforms ranging from inactivated whole virus vaccines over adenovirus‐vectored ...
openaire   +4 more sources

Mandating COVID-19 Vaccines [PDF]

JAMA, 2021
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines hold promise to control the pandemic, and help restore normal social and economic life. The Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for 2 mRNA vaccines and will likely issue full biologics licenses in the coming months.
Gostin, Lawrence O., Salmon, Daniel A., Larson, Heidi J.   +2 more
openaire   +3 more sources

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

New England Journal of Medicine, 2021
Background BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length spike protein.
Stephen J. Thomas, E. Moreira, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, John L. Perez, Gonzalo Pérez Marc, F. Polack, C. Zerbini, R. Bailey, K. Swanson, Xia Xu, Satrajit Roychoudhury, K. Koury, S. Bouguermouh, W. Kalina, David Cooper, R. Frenck, L. Hammitt, Ö. Türeci, H. Nell, A. Schaefer, S. Ünal, Qi Yang, P. Liberator, D. Tresnan, Susan H. Mather, P. Dormitzer, U. Şahin, W. Gruber, K. Jansen   +31 more
semanticscholar   +1 more source

The Time for COVID-19 Vaccination

Journal of Virology, 2021
The composition and dynamics of viral mutant spectra in infected individuals advise that to avoid selection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) escape mutants, vaccination campaigns for coronavirus disease 2019 (COVID-19) should be launched when disease incidence is low.
Domingo, Esteban, Perales, Celia
openaire   +4 more sources

A global survey of potential acceptance of a COVID-19 vaccine

Nature Medicine, 2020
Several coronavirus disease 2019 (COVID-19) vaccines are currently in human trials. In June 2020, we surveyed 13,426 people in 19 countries to determine potential acceptance rates and factors influencing acceptance of a COVID-19 vaccine.
J. Lazarus, S. Ratzan, Adam Palayew, L. Gostin, H. Larson, Kenneth H. Rabin, S. Kimball, A. El-Mohandes   +7 more
semanticscholar   +1 more source

COVID-19 Vaccine Development to Vaccination

Journal of Nepal Health Research Council, 2021
In the race for a safe and effective vaccine against Coronavirus disease-19 manufacturer plays a critical role throughout the development, clinical trial, manufacturing, supply, and vaccination phases. For the efficacy of Coronavirus disease-19 vaccine, proper transport, storage, vaccine carrier, adjuvant, dosage form and route of vaccine ...
Ashok Pandey, Pradeep Belbase, Ayuska Parajuli   +2 more
openaire   +2 more sources